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Abstract: Increased central arterial stiffness, involving accelerated vascular ageing of the 
aorta, is a powerful and independent risk factor for early mortality and provides prognostic 
information above and beyond traditional risk factors for cardiovascular disease (CVD). Central 
arterial stiffness is an important determinant of pulse pressure; therefore, any pathological 
increase may result in left ventricular hypertrophy and impaired coronary perfusion. Central 
artery stiffness can be assessed noninvasively by measurement of aortic pulse wave velocity, 
which is the gold standard for measurement of arterial stiffness. Earlier, it was believed that 
changes in arterial stiffness, which are primarily influenced by long-term pressure-dependent 
structural changes, may be slowed but not reversed by pharmacotherapy. Recent studies with 
drugs that inhibit the renin–angiotensin–aldosterone system, advanced glycation end products 
crosslink breakers, and endothelin antagonists suggest that blood pressure (BP)-independent 
reduction and reversal of arterial stiffness are feasible. We review the recent literature on the 
differential effect of antihypertensive agents either as monotherapy or combination therapy on 
arterial stiffness. Arterial stiffness is an emerging therapeutic target for CVD risk reduction; 
however, further clinical trials are required to confirm whether BP-independent changes in 
arterial stiffness directly translate to a reduction in CVD events.
Keywords: aortic pulse wave velocity, augmentation index, blood pressure, renin–angiotensin–
aldosterone system
Introduction
Hypertension is an increasingly prevalent condition, managed with a combination of 
lifestyle changes and increasingly by various pharmacological agents. These agents 
include the β-blockers, diuretics, calcium channel blockers (CCB), and drugs that 
interfere with the renin–angiotensin–aldosterone system (RAAS) pathway such as 
angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers 
(ARB), and aldosterone antagonists.
Currently, blood pressure (BP) is routinely measured in the clinical setting by brachial 
sphygmomanometry. However, prior to the routine use of the sphygmomanometer, the 
importance of arterial aging and the characteristics of the arterial pressure pulse wave 
as a bedside index of arterial aging were well documented.1 Abnormalities in the pulse 
wave shape were in fact used more than 100 years ago to diagnose hypertension and to 
demonstrate effects of drugs such as nitrates.1 Systolic pressure waves are augmented 
during transmission to the periphery; therefore, emerging evidence suggests that 
peripheral BP is only an indirect correlate of central aortic pressures. Importantly, 
the magnitude of such augmentation is dependent on stiffness of conduit vasculature, Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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described as central arterial stiffness. Central hemodynamic 
parameters, such as central systolic BP, pulse pressure (PP), 
and the augmentation index (AIx), are important determi-
nants of cardiac workload. These can be measured noninva-
sively at the radial artery using sensitive methods.1,2–6 AIx is 
calculated as the ratio of the augmentation pressure (AP), the 
amplification of peak systolic BP, which is in turn due to the 
reflected systolic wave, to the PP (AIx = AP/PP), Figure 1.2
Aortic pulse wave velocity (Ao-PWV) is recognized as the 
current gold-standard measure of arterial stiffness.2 Ao-PWV 
can be determined from carotid and femoral pressure wave-
forms obtained noninvasively by applanation tonometry. 
Pressure waveforms are referenced to a concurrently recorded 
electrocardiography (ECG), and carotid to femoral transit 
time (∆T) is calculated from the foot-to-foot time difference 
between carotid and femoral waveforms. The distance between 
the surface markings of the sternal notch and the femoral 
artery is used to estimate the path length between the carotid 
and femoral arteries (L) and Ao-PWV is computed as L/∆T. 
This technique is a reproducible and noninvasive method 
validated in a range of clinical settings and trials.2
Arterial stiffness, as evaluated by Ao-PWV, has been 
extensively studied in recent years and is an established 
independent predictor of cardiovascular risk; both fatal and 
nonfatal cardiovascular events and all cause mortality in 
hypertensive patients, in addition to an independent pre-
dictor of coronary heart disease and stroke in the healthy 
population.2,5
It is important to note the differences between AIx and 
Ao-PWV both of which are markers of arterial stiffness. 
AIx is known to be influenced by gender, heart rate, and 
body habitus in addition to BP and age.7,8 A transfer func-
tion derived from invasive studies is used to estimate central 
aortic pressure, APs, and AIx. Often there is poor correlation 
between Ao-PWV and AIx and some drugs can influence 
1 parameter independently of the other. In fact, AIx and 
Ao-PWV may not reflect the same arterial wall properties 
with AIx being a surrogate index for the stiffness of resistance 
vessels (arterioles), whereas Ao-PWV is an indicator of aortic 
stiffness. Indeed, AIx and Ao-PWV can change independently 
of each other due to the elastic properties of the aorta and 
the adaptive responses of the endothelium.7–9
Furthermore, the age-related changes in AIx and 
Ao-PWV are nonlinear. Some suggest that AIx is a more 
sensitive marker of central arterial stiffness in younger 
adults as compared with Ao-PWV, an index that changes 
Figure 1 Schematic of arterial pressure waveforms and calculation of augmentation index (AIx).3,4 A) Pulse waveforms in healthy compliant vasculature, timing of rebound 
wave reflection occurs during diastole (D). B) Pulse wave reflection is faster and earlier in stiffer arteries, thus amplifying the measured systolic BP peak (S), and reducing 
diastolic pressures (D), hence pulse pressure (PP) is increased (total height of combined pulse wave peak).
Abbreviation: AP, augmentation pressure.
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more prominently in older patients, in whom it is reported 
to better reflect arterial stiffness.10,11
Generally, Ao-PWV is accepted as the superior marker of 
arterial stiffness and many clinical studies have demonstrated 
the impact of aortic stiffness on cardiovascular disease (CVD) 
mortality and morbidity.2 A longitudinal study by Laurent 
et al12 demonstrated that aortic stiffness is a predictor of fatal 
stroke in patients with essential hypertension. In patients 
with chronic kidney disease, Blacher et al13 reported that 
an increase of 1 m/s Ao-PWV is associated with 34% (and 
14% after adjustments for other CVD risk factors) increase 
in cardiovascular and overall mortality. The reversibility of 
arterial stiffness in this patient group is a key modifiable 
risk factor for survival.14 Further epidemiological studies 
associate a raised arterial stiffness and central BP parameters 
with other underlying pathologies, such as left ventricular 
hypertrophy, carotid intima-media thickness, and endothelial 
dysfunction.3,15,16
A typical Ao-PWV in a healthy 25-year-old is 5 m/s, which 
then increases with age to around 8–9 m/s at 60–75 years.2 
Values above 13 m/s are a strong independent predictor of 
cardiovascular mortality.17 Arterial stiffness increases with 
normal ageing; however, as aforementioned, this ageing process 
is accelerated by coexisting hypertension, diabetes, metabolic 
syndrome, hypercholesterolemia, and arteriolosclerosis.2,4,16,18 
For example, patients with type 2 diabetes mellitus (T2DM) 
have a 1 m/s faster Ao-PWV than BP-matched nondiabetic 
subjects.2,16 Ethnic and gender variations in arterial stiffness 
have also been described.2 At present, normograms that 
describe the normal Ao-PWV for different ages are not 
available. However, such reference ranges specific for age and 
gender may be available for use in the near future.
The primary underlying pathology of increased arterial 
stiffness is attributable to the fragmentation and degradation 
of normal elastin, which is consequently replaced by stiffer 
abnormal collagen during the ageing process. Advanced 
glycation end products (AGEs) are abundance in the hyper-
glycemic and chronic diabetic patients.2,4,16,18 Nonenzymatic 
AGE crosslinkage affects both elastin and collagen, but 
preferentially collagen, which is also more stable and has 
a slower turnover rate. AGE interaction with the specific 
receptors for AGE further contributes to vascular damage 
and endothelial dysfunction resulting from the inflamma-
tory responses that are triggered, namely the increased 
expression of reactive oxygen species, proinflammatory 
cytokines, nuclear factor kappa B cells (NF-κB), growth 
factors, endothelin, vascular adhesion molecules, and the 
recruitment of monocytes.4,17,18
Oxidative and mechanical stresses mediate vascular 
remodeling of the extracellular matrix, via the enzymatic 
actions of the catabolic matrix metalloproteases. Inflamma-
tory cell and cytokine recruitment may contribute to the dys-
regulation of this enzyme family, thus resulting in pathological 
alterations of vascular wall composition and morphology, and 
an increased arterial stiffness.4,18 Furthermore, angiotensin II 
has been shown, both in vitro and in animal studies, to medi-
ate a number of effects from increased collagen synthesis to 
proliferation of smooth muscle cells, arterial wall fibrosis, 
accumulation and activation of inflammatory cells.19
There is significant variability in the effects of antihy-
pertensive drugs on arterial stiffness. This variability is due 
to the duration of treatment, the measure of arterial stiffness 
employed, and the magnitude of blood reduction observed. 
Importantly, as arteries are stiffer at higher BPs, due to the 
curvilinear relationship between arterial pressure and vol-
ume, arterial stiffness may decrease with any intervention 
that lowers BP.1 It is, therefore, often difficult to formally 
distinguish between the passive reductions in arterial stiff-
ness due to reduction in BP from the pressure-independent 
alterations of the arterial wall. Drugs, such as ACE-I, ARB, 
and aldosterone antagonists, seem to improve large artery 
compliance independently of BP changes, probably acutely 
by inducing functional changes such as vascular smooth 
muscular relaxation and in the long term by decreased arte-
rial wall thickness, collagen content, and reversal of smooth 
muscle cell hypertrophy.2,6,7,16,18,19
Research addressing the mechanism of action, direct class 
effects, and efficacies of antihypertensive therapies on BP 
has been extensively reviewed and national and international 
guidance and consensus statements are available;20,21 hence, 
this review focuses on the recent literature that compares 
and contrasts head-to-head trials of antihypertensive therapy 
on arterial stiffness as assessed primarily by Ao-PWV and 
the AIx.
Tables 1 and 2 summarize the main effects of the major 
classes of antihypertensive agents on Ao-PWV and AIx when 
used as monotherapy and in combination therapy.
Conduit Artery Function Evaluation 
(CAFE) study: combination of 
β-blocker and bendroflumethiazide 
vs CCB and ACE-I
This landmark randomized, controlled clinical trial was a 
  vascular-orientated substudy of the Anglo-  Scandinavian 
Cardiac Outcomes Trial.6 Patients had either untreated Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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augmentation; and the predictive value of treated central BP 
on cardiovascular mortality and associated outcomes.6,22 In 
the CAFE study, 2,073 individuals were included in the final 
analysis and baseline demographic and clinical characteristics 
were similar in the 2 groups.
The primary antihypertensive (maximum dose 100 mg/
day of atenolol or maximum dose 10 mg/day of amlodipine) 
was administered following a specific stepwise algorithm 
with bendroflumethiazide (maximum dose 2.5 mg/day 
in atenolol arm) or perindopril (maximum dose 8 mg/
day in amlodipine arm) added as necessary in order to 
achieve target BPs of ,140/90 mm Hg for nondiabetics 
and ,130/80 mm Hg for patients with diabetes. Antihy-
pertensive drug doses were revised regularly at 6-monthly 
intervals and arterial stiffness measurements averaging 3.4 
follow-up measurements per patient were available at the 
end of the study. Ninety-five percent of patients were on at 
least 2 BP-lowering drugs, with 56% on amlodipine ± per-
indopril combination and 60% on atenolol ± thiazide 
combination.6
Applanation tonometry for central aortic pressure, 
AIx and Ao-PWV were performed along with brachial BP 
recordings. In this study, BP load for each treatment arm was 
presented as the mean area under the curve (AUC). From 
baseline, significant reductions in brachial BP were observed 
in both groups. However, there was an insignificant difference 
in brachial systolic BPs throughout the CAFE study (AUC 
difference, 0.7 mm Hg; 95% confidence interval [CI], −0.4 
to 1.7; P = 0.2).
In contrast to the brachial BP results, derived central 
aortic systolic pressures were substantially lower with 
amlodipine ± perindopril-based therapy (AUC difference, 
4.3 mm Hg; 95% CI, 3.3–5.4; P , 0.0001) as compared 
with atenolol ± bendroflumethiazide. Similar significant dif-
ferences in central aortic PP and to a smaller extent, central 
diastolic BP in favor of amlodipine ± perindopril were also 
observed. AIx and central APs decrease to a greater extent 
with amlodipine ± perindopril. Ao-PWV , however, did not 
differ between the 2 groups. This suggests that increased 
wave reflections from distal sites along the arterial tree were 
primarily responsible for the observed changes in AIx. Impor-
tant clinical outcomes were evaluated in this study albeit as a 
secondary outcome. The post hoc defined composite outcomes 
were cardiovascular events/procedures and development of 
renal impairment.
Results showed that measures of arterial stiffness such 
as central aortic PP and brachial PP; central aortic pressure 
Table 1 effects of different antihypertensive agents on arterial 
stiffness
Class Effect on  
Ao-PWV
Effect on central aortic 
pressures and AIx
Thiazide diuretics24 Neutral Neutral
α-blockers
Doxazosin37,38 Neutral Neutral
β-blockers
Atenolol25,28,29 Reduce Increase
Nebivolol,35 vasodilating 
β-blocker
Reduce Reduce
CCB23,28,32 Reduce Reduce
RAAS blockers
Aldosterone antagonists32 Reduce Reduce
ACe-I28,33 Reduce Reduce
ARB23,29,33 Reduce Reduce
Abbreviations: ACe-I, ACe inhibitor; ARB, angiotensin receptor blocker; AIx, 
augmentation index; Ao-Pwv, aortic pulse wave velocity; CCB, calcium channel 
blocker; RAAS, renin–angiotensin–aldosterone system.
Table 2 effects of combination therapy of different classes of 
antihypertensive agents on arterial stiffness
Combination Effect on  
Ao-PWV
Effect on central  
aortic pressures 
and AIx
ACe-I + CCB6 Neutral Reduce
Thiazide + potassium-sparing 
(amiloride) diuretic26,27
Neutral Reduce
ACe-I + indapamide25 Reduce Reduce
ARB + CCB24 Reduce Reduce
ARB + thiazide diuretic23 Reduce Reduce
Abbreviations: ACe-I, ACe inhibitor; ARB, angiotensin receptor blocker; AIx, 
augmentation index; Ao-Pwv, aortic pulse wave velocity; CCB, calcium channel 
blocker.
hypertension or treated hypertension, and to be eligible, 
patients had to have at least 3 additional cardiovascular risk 
factors from the following: male sex, smoker, age . 55 years, 
left ventricular hypertrophy, ECG abnormalities consistent 
with evidence of ischemic changes, T2DM, peripheral arte-
rial disease, cerebrovascular disease, microalbuminuria or 
proteinuria, a ratio of total plasma cholesterol to high-density 
lipoprotein cholesterol of $6, or a family history of prema-
ture coronary heart disease. Eligible patients were random-
ized to 2 treatment regimes, the aims being to compare the 
effects of traditional combination antihypertensive therapy of 
atenolol ± thiazide with a more contemporary combination 
therapy of the dihydropyridine CCB amlodipine ± ACE-I 
perindopril. The objectives of the CAFE study were to pro-
spectively study the effects of these combinations on the rela-
tionship between central and peripheral arterial BP; arterial 
stiffness as indicated by the extent of arterial pressure wave Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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wave augmentation; and outgoing pressure wave height were 
all significantly associated with the composite end point. 
However, following adjustment for baseline age and other 
risk factors, only central aortic PP remained significantly 
associated with the composite clinical outcome.6
Combination of an ARB  
and hydrochlorothiazide vs CCB
We recently demonstrated in a double-blind, parallel group 
study, the brachial and central aortic BP-independent effects 
of an ARB on Ao-PWV .23 We studied 144 T2DM patients 
with systolic hypertension (systolic BP $ 140 mm Hg and 
PP $ 60 mm Hg) and microalbuminuria who were random-
ized to receive the ARB valsartan (160 mg/day) ± hydrochlo-
rothiazide (25 mg/day) combination therapy (Val/HCTZ), or 
dihydropyridine CCB, amlodipine (10 mg/day) for 24 weeks 
following a 4-week washout with moxonidine (400 mcg/day), 
a centrally acting antihypertensive agent with limited effects 
on arterial stiffness.23 HCTZ was added to the ARB to ensure 
comparable BP-lowering effects. Importantly, the mechanism 
of action of HCTZ does not involve alteration in vascular 
tone or arterial wall properties. This approach enabled the 
BP-independent comparison of 2 widely used antihyperten-
sive classes on Ao-PWV which was the primary end point 
of the study.
Both brachial and central aortic systolic BP, diastolic 
BP, and PP fell significantly, and similarly after 24-week 
treatment in both groups, mean brachial systolic BP (95% 
CI) fell (Val/HCTZ vs amlodipine −23.7 [−28.5, −18.9] vs 
−19.4 [−24.1, −14.6] mm Hg; brachial diastolic BP −9.4 
[−11.9, −6.9] vs −7.3 [−9.8, −4.9] mm Hg; and brachial 
PP −14.3 [−17.7, −10.8] vs −12.2 [−15.5, −8.8] mm Hg). 
There were no significant differences in the decrease of 
brachial BP between the 2 groups. Furthermore, there were 
no between-group differences in mean arterial pressure 
(MAP) and MAP change. After 24-week treatment, similar 
significant reductions in central aortic systolic BP (Val/
HCTZ vs amlodipine −23.6 [−28.7, −18.6] vs −21.1 [−26.0, 
−16.3] mm Hg; central diastolic BP −10.4 [−12.9, −7.9] vs 
−9.1 [−11.5, −6.8] mm Hg; and central aortic PP −13.3 
[−16.9, −9.7] vs −11.9 [−15.4, −8.5] mm Hg) were observed 
with no significant between treatment-group differences. 
Interestingly, after 24 weeks attained mean (standard 
deviation), brachial and central PP were similar in the 2 
groups (61.6 [13.6] and 47.3 [14.1] mm Hg in the valsartan/
HCTZ group and 61.5 [12.2] and 47.3 [9.9] mm Hg in the 
amlodipine group).23
Mean (95% CI) Ao-PWV was reduced from baseline by 
1.8 (−2.4 to −1.3) m/s in Val/HCTZ group (P , 0.0001) and 
by 0.7 (−1.3 to −0.2) in amlodipine group (P = 0.01) with 
an estimated mean (95% CI) difference in Ao-PWV change 
from baseline between the Val/HCTZ and amlodipine group 
of −1.1 (−1.8 to −0.5) m/s (P = 0.001). Significant   differences 
between the 2 groups regarding the ability to reduce Ao-PWV 
were observed early following 12 weeks of treatment. 
Albuminuria, a biomarker of cardiorenal risk decrease sig-
nificantly only in the Val/HCTZ arm. Of note, changes in 
albumin excretion rate and Ao-PWV were not correlated. 
Our results suggest that the Val/HCTZ combination improves 
arterial stiffness as assessed by Ao-PWV to a significantly 
greater extent than CCB amlodipine despite similar central 
and brachial BP control.23 This effect may explain the specific 
BP-independent cardiorenal protective properties of RAAS 
blockade observed in clinical trials.20,21
Combination of an ARB  
and CCB vs ARB and HCTZ
Matsui et al24 recently studied the effects of add-on treatment 
with a CCB or diuretic to an ARB on Ao-PWV and central 
aortic pressures. In this open-label study, 207 patients 
with essential hypertension received the ARB olmesartan 
as monotherapy (20 mg OD) for 12 weeks and were 
then randomized to add-on use of the CCB azelnidipine 
(n = 103, 16 mg OD) or HCTZ (n = 104, 12.5 mg OD) for 
24 weeks.24 The authors report that 16 mg OD of azelnidipine 
is equivalent to a 5 mg OD of amlodipine. After 24 weeks, 
there was a significantly greater reduction in central aortic 
systolic BP in the olmesartan/azelnidipine group than that in 
the olmesartan/HCTZ group with a between-group difference 
of 5.2 mm Hg (95% CI, 0.3–10.2 mm Hg; P = 0.039), despite 
similar effects on brachial BP. Ao-PWV fell significantly 
in both groups but was reduced to a greater extent in the 
olmesartan/azelnidipine group than in the olmesartan/HCTZ 
group with a between-group difference of 0.8 m/s (95% 
CI, 0.5–1.1 m/s; P , 0.001). AIx (adjusted for heart rate) 
also fell to a greater extent in the olmesartan/azelnidipine 
group with a significant between-group difference of 2.8% 
(95% CI, 1.3–4.4; P , 0.001). Of note, MAP decreased to a 
significantly greater extent by 4.5 mm Hg (95% CI, 1.5–7.6; 
P , 0.004) in the olmesartan/azelnidipine group. Following 
adjustment for this difference in MAP, the effect on Ao-PWV 
reduction by olmesartan/azelnidipine remained significant 
but was somewhat diminished with a between-group 
difference of 0.5 m/s (95% CI, 0.2–0.7; P , 0.001).24Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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PREterax in regression of 
Arterial Stiffness in a contrOlled 
double-bliNd (REASON) study: 
combination of an ACE-I  
and diuretic vs β-blocker
The REASON trial was a randomized, double-blind 
study to compare a very low-dose combination of 
ACE-I, perindopril (2 mg) ± nonthiazide sulphonamide 
diuretic, indapamide (0.625 mg; Per/Ind) vs conven-
tional β-blocker, atenolol (50 mg) in 471 patients with 
uncomplicated essential hypertension.25 Significantly 
greater reductions in brachial systolic BP and PP were 
observed in the Per/Ind group than in the atenolol group 
(−23.1 ± 15.6 vs −16.2 ± 16.0 mm Hg; P , 0.001) and 
(−9.9 ± 12.4 vs −3.3 ± 13.5 mm Hg; P , 0.001), respec-
tively. Brachial diastolic BP was also reduced significantly 
and similarly in both groups.
A significantly greater decrease in central (carotid and 
aortic) BPs was observed in the Per/Ind group as compared 
with atenolol. No significant between-group differences 
in the Ao-PWV reductions were observed. However, AIx 
was reduced to a significantly greater extent with Per/Ind. 
Atenolol lengthens the systolic ejection time while also 
delaying the peak of the forward pressure wave; hence this 
may explain the increased augmentation of the pressure wave 
reflection observed.25
ACE-I vs combination therapy  
with amiloride and HCTZ
A smaller study of 77 elderly hypertensive patients compared 
and contrasted the effect of perindopril (2–8 mg/day) or a 
diuretic combination of HCTZ (12.5–50 mg/day) ± amiloride 
(1.25–5 mg/day) for 9 months, after a 1-month washout 
with placebo therapy, on carotid artery distensibility and 
compliance.26 Both of these parameters improved signifi-
cantly in the 2 groups. Of note, the authors suggested that 
the significant decrease in carotid artery stiffness observed 
was directly related to the decrease in mean BP observed in 
both groups.26
Other combinations  
of antihypertensive agents
Bénétos et al27 compared HCTZ (50 mg) ± amiloride (5 mg) 
with captopril (50 mg) ± HCTZ (25 mg) combination and 
showed that the ACE-I/diuretic combination decreased 
arterial wave reflection to a greater extent than the diuretics 
alone, despite similar BP reductions in both groups.
Comparison of ACE-I vs β-blocker 
vs CCB vs thiazide diuretic
A recently published study of 59 treatment naive patients 
with isolated systolic hypertension studied the effects of 
monotherapy with perindopril or atenolol or lercanidipine or 
bendrofluazide for 10 weeks on arterial stiffness, as measured 
by radial artery tonometry for estimation of central aortic pres-
sures, AIx, and Ao-PWV .28 After a 2-week run-in of placebo 
therapy, participants were randomized to active monotherapy 
that was administered in daily doses (4.0 mg perindopril, 
50.0 mg atenolol, 10.0 mg lercanidipine, or 2.5 mg bendroflu-
azide). Peripheral brachial PP and systolic BP were reduced 
similarly and significantly in all groups. Atenolol failed to 
reduce central PP, whereas the other antihypertensive classes 
significantly reduced all the central hemodynamic parameters. 
AIx was increased with atenolol, an observation also dem-
onstrated in other larger studies with this agent.25 Ao-PWV , 
however, remained unchanged in all 4 treatment arms. These 
results suggest that 10 weeks of treatment with submaximal 
doses of antihypertensive therapy may be insufficient to 
demonstrate significant changes in Ao-PWV . Alternatively, 
this cohort of patients may have blunted responsiveness to 
antihypertensives vis-à-vis reduction in Ao-PWV .28
A smaller study in 21 treatment naive hypertensive 
patients compared the effects of an ARB eprosartan with 
atenolol. There was a greater reduction in central systolic BP 
and Ao-PWV (0.8 ± 0.1 vs 0.5 ± 0.1 m/s; P , 0.005), in the 
atenolol arm compared with eprosartan arm, after 6 weeks of 
treatment despite similar effects on brachial BP. Of interest, 
an increase in AIx was observed with atenolol as compared 
to a reduction in the ARB treatment arm.29
Aldosterone antagonist vs CCB
Animal studies have demonstrated that aldosterone antagonist, 
spironolactone prevents the accumulation of aortic collagen 
and reduces aortic stiffness.30 Interestingly, in hypertensive 
subjects, there is positive correlation between increase in 
plasma aldosterone and arterial stiffness, an effect which also 
appears independent of BP.31 White et al32 compared effects of 
the aldosterone antagonist eplerenone with CCB amlodipine, 
for 24 weeks on arterial stiffness in a cohort 269 patients with 
systolic hypertension. Patients were randomly assigned to 
either eplerenone (50–200 mg/day) or amlodipine (2.5–10 mg/
day).32 After 24 weeks of therapy, reductions in brachial 
systolic BP was similar in both treatment arms (eplerenone, 
−20.5 ± 1.1 mm Hg; amlodipine, −20.1 ± 1.1 mm Hg). PP also 
decreases similarly from baseline in both groups (eplerenone, 
−15.9 mm Hg;   amlodipine, −13.4 mm Hg). At the end of the Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Antihypertensive agents and arterial stiffness
study, Ao-PWV had decreased significantly from baseline 
in the eplerenone and amlodipine groups by 2.1 and 2.4 m/s, 
respectively; however, there was no significant difference 
between the 2 treatment groups.32
Combination therapy with ACE-I 
and ARB vs monotherapy
The combination of valsartan and captopril on Ao-PWV and 
AIx was studied in 12 patients with essential hypertension. 
In this short, 4-week randomized crossover study, valsartan 
(160 mg/day) vs captopril (100 mg/day) was compared, 
followed by comparison between combination therapy and 
monotherapy. Combination therapy reduced Ao-PWV and 
AIx more when compared with monotherapy, even when 
differences in BP were corrected for. The effects of valsartan 
vs captopril on Ao-PWV and AIx were similar.33 However, 
in light of recent concerns on the safety of combination 
therapy with an ACE-I and ARB on renal end points and 
lack of demonstrable cardiovascular benefits, it is unclear 
whether such an approach should be continued in clinical 
practice.34
β-blockers, α-blockers, and nitrates
Some authors have suggested that β-blockers, with vasodilat-
ing properties, such as nebivolol may have a beneficial effect 
on wave reflection. A recent study compared atenolol with 
nebivolol in 40 untreated patients with hypertension. Both 
drugs reduced Ao-PWV to a similar extent. However, only 
nebivolol demonstrated a reduction in AIx.35 Another study 
in 16 treatment naive patients with isolated systolic hyperten-
sion showed similar results. Nebivolol and atenolol reduced 
brachial BP and Ao-PWV to a similar degree. Interestingly, 
in this study, nebivolol reduced central aortic PP more than 
atenolol with a less pronounced rise in AIx.36
There is conflicting evidence on the effects of α-receptor 
blocking agents such as doxazosin on arterial stiffness. One 
nonrandomized study reported improvements in Ao-PWV 
and AIx.37 However, another study demonstrated reduction 
in AIx only.38
Nitrates have a pronounced acute effect on the arterial 
pressure waveform but have limited effect on aortic 
stiffness.2,39 At present, however, there are no long-term stud-
ies evaluating the effects of nitrates on markers of arterial 
stiffness with most studies being of short duration.
Endothelin and arterial stiffness
Vuurmans et al40 demonstrated that infusion of endothelin-1, 
at concentrations found in renal disease, into healthy 
volunteers reduced brachial MAP, Ao-PWV, and AIx. 
The   concomitant use of an endothelin-1 receptor blocker 
prevented these effects.40
In patients with nondiabetic chronic kidney disease and 
proteinuria, acute use of a selective endothelin-A receptor 
antagonist reduced BP, proteinuria, and arterial stiffness 
when added to standard treatment.41 The effects on arte-
rial stiffness appeared at least, in part independent of BP. 
However, long-term studies are required to confirm these 
preliminary findings. Further concerns have been raised 
recently on the use of endothelin-A receptor antagonists in 
routine clinical practice as they can increase the risk of fluid 
retention and congestive heart failure in T2DM patients with 
nephropathy.42
Conclusion
There is emerging evidence that modulation of arterial 
stiffness independent of BP reduction is now possible. 
Importantly, data from patients with end stage renal disease 
indicate that reversibility in Ao-PWV in response to ACE-I 
treatment is associated with reduced mortality independent 
of brachial BP. Our data and that of other authors suggest 
that drugs that interfere with RAAS reduce arterial stiffness, 
an effect that may be independent of their BP-lowering 
effects. The results from the CAFE study suggest that 
greater cardiovascular protection is observed with drugs 
that differentially lower central aortic pressures rather 
than only brachial BP. Many hypertensive patients will 
require combination therapy to ensure optimal BP control. 
The current evidence indicates that RAAS blockade with 
an ACE-I or ARB in combination with a thiazide diuretic 
and or CCB are therapies that are most likely to amelio-
rate arterial ageing and reduce arterial stiffness. However, 
further long-term studies are required to conclusively 
prove that reduction in Ao-PWV or other parameters of 
arterial stiffness per se directly translates to reduction in 
cardiovascular events.
Summary of terms
Arterial elasticity: elastic modulus is defined as the pressure 
change needed for a theoretical 100% stretch from diameter 
at rest.
Arterial distensibility: the inverse of the elastic modulus 
ie, the relative change in diameter (or area) for a given pres-
sure change.
Arterial compliance: absolute diameter (or area) change 
for any given pressure. This is a measure of the capacity of the 
arterial system to accommodate further increase in volume.Integrated Blood Pressure Control 2010:3 submit your manuscript | www.dovepress.com
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